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Background:  Data are sparse and inconsistent regarding whether local thrombolytic therapy (by placement of central venous catheters) 
reduces mortality, expense or hospital stay in comparison with systemic administration of thrombolytics with acute pulmonary embolism (PE).
methods:  In-hospital all-cause mortality according to local versus systemic administration of thrombolytics was determined in patients with 
pulmonary embolism who were discharged from short-stay hospitals throughout the United States from 2008 to 2012 by using data from 
the Nationwide Inpatient Sample.
results:  Among 6279 patients with pulmonary embolism treated with thrombolysis, 1605 (25%) received locally administered therapy. 
Local catheter-directed thrombolysis (CDT) was reserved for patients with higher co-morbidities. In-hospital all-cause mortality was with 
CDT was 25.2% vs 11.66% for systemic thrombolysis (OR 2.46, 95% CI 2.13-2.84, P<0.001). Mean total hospitalization charge ($147,245 
vs $96,561) as well as length of stay (9 days vs 7 days) was also significantly higher with CDT compared with systemic thrombolysis. In 
a propensity score-adjusted model, the mortality, hospitalization charge and length of stay while was numerically lower, but still remained 
significantly higher for CDT in comparison with systemic thrombolysis (Table 1).
conclusion:  CDT compared with systemic thrombolysis for PE doesnot appear to be associated with lower mortality, cost or duration of 
hospitalization.
Table 1.
Unadjusted (N=6279) CDT Systemic Thrombolysis P-value Propensity Score Adjusted (N=2816) CDT Systemic Thrombolysis P-value
Mean Age (SD) 58(17) 56(17) <0.001 58 59 0.1
Women(%) 57 49 <0.001 57 60 0.15
Caucasian(%) 64.3 64.9 0.65 73 73 0.83
African-American(%) 15.1 14.1 0.29 17 19 0.33
Others(%) 20.6 21 0.36 10 8 0.39
AMI(%) 8.54 5.54 <0.001 8.6 8.9 0.79
CHF(%) 15.57 9.62 <0.001 0.15 0.15 0.75
PVD(%) 2.49 2.4 0.83 2.6 2.3 0.54
Stroke/TIA(%) 7.6 4.64 <0.001 7.8 8 0.83
Dementia(%) 0.12 0.08 0.66 0.14 0.14 1
COPD(%) 15.6 13.1 0.006 16.5 17.1 0.65
Rheumatoid Disease(%) 2.37 2.05 0.45 2.6 2.9 0.49
Peptic Ulcer Disease(%) 1.49 0.58 0.0002 1.3 0.9 0.29
Mild Liver Disease(%) 0.12 0.17 0.68 0.1 0 0.15
Diabetes(%) 15.14 14.03 0.27 15 15 0.59
Diabetes with Complications(%) 2.12 1.41 0.026 2.2 1.1 0.027
Hemiplegia/Paraplegia(%) 3.05 1.43 <0.001 3.1 2.9 0.74
Renal Disease(%) 9.2 6.2 <0.001 9.4 7.9 0.16
Cancer(%) 5.48 4.45 0.092 5.9 6.5 0.48
Severe Liver Disease(%) 0.63 0.12 0.001 0.5 0.4 0.56
Metastatic Cancer(%) 4.98 4 0.092 5 5.3 0.73
AIDS(%) 0.69 0.19 0.003 0.6 0.4 0.17
Outcomes
Unadjusted Propensity Score Adjusted
Death(%) 24.52 11.66 <0.001 24.9 11.3 <0.001
Total Hospitalization Charge($) 147,345 96,561 <0.001 122,112 72,748 <0.001
Length of Stay (Days) 9 7 <0.001 9 5 <0.001
